+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients



Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients



Health and Quality of Life Outcomes 11: 105



Trials have not assessed the effect of dalfampridine-extended release (dalfampridine-ER) on health utility. We sought to evaluate the effect of dalfampridine-ER tablets (prolonged-release fampridine in Europe) on health utility in patients with multiple sclerosis (MS) by mapping subjects' individual item scores from the 12-Item Multiple Sclerosis Walking Scale (MSWS-12) onto the Euroqol 5-Dimension (EQ-5D) health utility index. Data from study MS-F203, a randomized trial of dalfampridine-ER tablets, 10 mg twice daily, in patients with MS, were used to calculate the health utility scores with two MSWS-12 to EQ-5D mapping equations (one derived in a North American [NA] registry, the other a United Kingdom [UK] registry). MS-F203 participants were categorized as dalfampridine-ER 20%-responders (achieving ≥20% improvement on the Timed 25-Foot Walk), dalfampridine-ER 20%-nonresponders (<20% improvement), or placebo patients. Mean change in health utility scores from baseline to each double-blind treatment evaluation (visits 3-6 occurring at post-randomization weeks 2, 6, 10, and 14) and each off-drug follow-up evaluation (visits 7-8 occurring at weeks 16 and 18) were calculated and reported as effect sizes (ESs). Using the NA-derived equation, dalfampridine-ER 20%-responders demonstrated improvement in health utility vs. placebo; starting at week 6 (mean difference in ES = 0.44, p = 0.002) and maintained at weeks 10 (ES = 0.41, p = 0.01) and 14 (ES = 0.71, p < 0.001). These improvements were no longer evident after dalfampridine-ER was discontinued (p > 0.05 at weeks 16 and 18). Dalfampridine-ER 20%-nonresponders did not show improvement vs. placebo at any visit (p > 0.05 for all). When using the UK-derived equation, improvement was seen in dalfampridine-ER 20%-responders vs. placebo at weeks 2, 6, 10, and 14 (ESs = 0.49, 0.55, 0.59, and 0.99; p < 0.03 for all), but not when dalfampridine-ER was discontinued (weeks 16 and 18; p > 0.05 for both). Dalfampridine-ER 20%-nonresponders showed no improvement at any visit (p > 0.05 for all). Regardless of the equation used, dalfampridine-ER response was associated with an improvement in health utility.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036975665

Download citation: RISBibTeXText

PMID: 23799913

DOI: 10.1186/1477-7525-11-105


Related references

Estimation of the effect of dalfampridine on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients. 2013

The use of multiple sclerosis condition-specific measures to inform health policy decision-making: mapping from the MSWS-12 to the EQ-5D. Multiple Sclerosis 18(6): 853-861, 2012

Mapping of Multiple Sclerosis Walking Scale (MSWS-12) to five-dimension EuroQol (EQ-5D) health outcomes: an independent validation in a randomized control cohort. Patient Related Outcome Measures 7: 13-18, 2016

Dalfampridine: a medication to improve walking in patients with multiple sclerosis. Annals of PharmacoTherapy 46(7-8): 1010-1015, 2012

Long-term effects of dalfampridine in patients with multiple sclerosis. Journal of the Neurological Sciences 337(1-2): 18-24, 2014

Dalfampridine: review of its efficacy in improving gait in patients with multiple sclerosis. Journal of Central Nervous System Disease 3: 87-93, 2011

Dalfampridine may activate latent trigeminal neuralgia in patients with multiple sclerosis. Neurology 83(18): 1610-1612, 2014

Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D. Value in Health 15(8): 1084-1091, 2012

A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosis. International Journal of Ms Care 16(3): 153-160, 2014

Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis. Neuropsychiatric Disease and Treatment 7: 229-239, 2011

Population pharmacokinetics and pharmacodynamics of dalfampridine-ER in healthy volunteers and in patients with multiple sclerosis. Current Medical Research and Opinion 29(12): 1637-1645, 2013

Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosis. Current Medical Research and Opinion 29(12): 1627-1636, 2013

Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis. Core Evidence 5: 107-112, 2010

Assessment of confirmed urinary tract infection in patients treated with dalfampridine for multiple sclerosis. Postgraduate Medicine 127(2): 218-222, 2015

Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Current Medical Research and Opinion 27(7): 1415-1423, 2011